Hepatitis C Screening in Intravenuos Drug Users in Golpayegan, Isfahan through Community Announcement: Pilot Study

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Infectious Diseases, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

2 AIDS, Hepatitis and Sexual Transmitted Diseases Expert, Isfahan University of Medical Sciences Health Center, Isfahan, Iran.

3 Disease Control Unit, Golpayegan ince Health Center, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Technical Manager, Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

5 Researcher, Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

6 Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

7 Associate Professor, Department of Gastroenterology, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Intravenous drug abuse is a worldwide problem with side effects as hepatitis C. Hepattis C infection, which has severe complications like cirrosis and hepatocellular carcinoma, is a tragedy for communities; so, screening it in intravenous drug abusers has a lot of benefits. According to lack of a community based study in Isfahan, Iran, this pilot study carried out in Golpayegan city in Isfahan Province.Methods: In a cross sectional pilot study, hepatitis C in intravenous drug abusers population in Golpaygan, Isfahan was screened by community annaouncement method. After co-opperation with managers, administrative stafs and all of the stakeholders, the study population was invited to refference laboratories where blood samples were chpsen and tested for anti-HCV-Ab. The results were sent privately and patients were invited to participate in educational and treatment procedure.Finding: From 136 persons participated voluntarily, 28 were anti-HCV-Ab positive (19.8%).Conclusion: In this pilot study, 85% of estimated population was participated that is excellent experience for larger studies.

Keywords

References

  1. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Saberi Zafarghandi MB, et al. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system. AIDS Behav 2008; 12(4 Suppl): S7-12.
  2. Cocozella DR, Albuquerque MM, Borzi S, Bar- rio M, Dascenzo V, Santecchia JC, et al. [Preva- lence of hepatic involvement, alcoholism, hepatis B, C and HIV in patients with background histo- ry of drug use]. Acta Gastroenterol Latinoam 2003; 33(4): 177-81.
  3. Etard JF, Colbachini P, Dromigny JA, Perrier- Gros-Claude JD. Hepatitis C antibodies among blood donors, Senegal, 2001. Emerg Infect Dis 2003; 9(11): 1492-3.
  4. Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, hepatitis C, and hepatitis B infections and associated risk beha- vior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis 2007; 13(9): 1327-31.
  5. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41-6.
  6. Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Mi- crobiol Infect 2009; 15 Suppl 5: 10-4.
  7. Farzanegan H. The prevalence of HBs Ag, HBs Ab and HBs Ab in Healthy blood donor and high risk group in Iran. Sang 1979; 73-182.
  8. Loebstein R, Mahagna R, Maor Y, Kurnik D, Elbaz E, Halkin H, et al. Hepatitis C, B, and hu- man immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Isr Med Assoc J 2008; 10(11): 775-8.
  9. Rahbar RA, Rooholamini S, Khoshnood K. Pre- valence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. In- ternational Juornal of Drug Policy 2004; 15(2): 151-5.
  10. Kuo I, ul-Hasan S, Galai N, Thomas DL, Zafar T, Ahmed MA, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006; 3: 26.
  11. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug us- ers in Flanders: determinants and geographic dif- ferences. Epidemiol Infect 2005; 133(1): 127-36.
  12. Fuglsang T, Fouchard JR, Ege PP. [Prevalence of HIV and hepatitis B and C among drug addicts in the city of Copenhagen]. Ugeskr Laeger 2000; 162(27): 3860-4.
  13. Navarro VJ, St Louis TE, Bell BP. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. J Clin Gastroenterol 2003; 36(5): 431-5.
Journal of Isfahan Medical School
Volume 28, Issue 0
November and December 2011
Pages 1581-1586

Files

History

  • Receive Date: 03 April 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics